





Molecular Anti-diabetic Potential of Medicinal Plants: A Review



Sara Ouari¹ , Nadia Benzidane¹, Noureddine Bribi² , Lekhmici Arrar¹  and Maria Trapali^{3,*} 

¹Laboratory of Applied Biochemistry, Faculty of Nature and Life Science, University Ferhat Abbas Setif 1, Setif, Algeria

²Laboratory of Plant Biotechnology and Ethnobotany, Faculty of Nature and Life Sciences, University of Bejaia, Bejaia, Algeria

³Laboratory of Chemistry and Biochemistry and Cosmetic Science, Department of Biomedical Medicine, University of West Attica, Egaleo, Attiki, Greece

Abstract:

Introduction: Diabetes mellitus is a chronic metabolic condition characterized by hyperglycemia due to either insulin resistance, lack of insulin production, and/or secretion. The global rates of infection are increasing, especially in low- and middle-income countries; thus, exploring novel and safer therapeutic options has become essential. This review aims to compile and analyze existing data on the anti-diabetic properties of selected medicinal plants, focusing on their phytochemical composition, molecular mechanisms of action, and potential therapeutic roles in glucose homeostasis.

Methods: A comprehensive literature search was conducted using databases such as Scopus, ScienceDirect, and Google Scholar. Sixteen medicinal plants traditionally used for diabetes management were identified and examined based on multiple experimental studies.

Results: Phytochemicals such as flavonoids, polyphenols, saponins, and terpenoids from these plants exhibit anti-diabetic effects through multiple mechanisms: modulation of glucose transporters (*e.g.*, GLUT4), activation of insulin signaling pathways (*e.g.*, PI3K/Akt), inhibition of digestive enzymes (*e.g.*, α -amylase, α -glucosidase), promotion of insulin secretion, and mitigation of oxidative stress.

Discussion: Notably, compounds like quercetin, kaempferol, berberine, and gymnemic acid have shown significant promise.

Conclusion: Medicinal plants present a rich source of bioactive compounds with multi-targeted mechanisms relevant to diabetes management. Further pharmacological investigations are necessary to establish their therapeutic efficacy and safety, enabling the development of phytochemical-based interventions for diabetes.

Keywords: Diabetes mellitus, Medicinal plants, Phytochemicals, Hypoglycemic activity, Insulin signaling, Oxidative stress.

© 2026 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Address correspondence to this author at the Laboratory of Chemistry and Biochemistry and Cosmetic Science, Department of Biomedical Medicine, University of West Attica, Egaleo, Attiki, Greece; Email: ymaria@uniwa.gr

Cite as: Ouari S, Benzidane N, Bribi N, Arrar L, Trapali M. Molecular Anti-diabetic Potential of Medicinal Plants: A Review. Open Biochem J, 2026; 20: e1874091X465477. <http://dx.doi.org/10.2174/011874091X465477260531222257>



Received: December 06, 2025

Revised: February 16, 2026

Accepted: March 03, 2026

Published: June 03, 2026



Send Orders for Reprints to
reprints@benthamscience.net

1. INTRODUCTION

Herbal therapy has been used for several thousand years and has gained increasing attention in recent years for its potential in managing many illnesses, and serves as a valuable basis for identifying new therapeutic agents [1, 2]. Several medicinal plants (various herbs, fruits, and grains) are reported for their anti-diabetic activity. This healing effect is due to the nature of phytochemicals present in them, a wide variety of secondary metabolites, including: alkaloids, glycosides, tannins, essential oils, and terpenoids; which in turn depend on the growing conditions, timing, and process of harvesting, and light and air exposure of the plant [3-5]. Diabetes is one of the most prevalent chronic Non-Communicable Diseases (NCDs) worldwide, the fourth leading cause of death after cardiovascular diseases, cancers, and chronic respiratory diseases [6]. In 2024, the IDF estimated that 11.1% (589 million) of adults worldwide were living with diabetes. Most of them (81%) are concentrated in developing countries, where limited access to diagnosis and proper treatment exacerbates the disease burden [7]. Diabetes requires early diagnosis, and its management includes lifestyle modifications, pharmacotherapy, and, in certain cases, insulin therapy [4]. Nonetheless, these conventional approaches are often linked to adverse effects, which has fueled growing interest in medicinal plants as alternative or complementary therapeutic options [8]. For more efficient and risk-free methods of reducing glucose, Numerous medicinal plants have shown promising glucose-lowering effects *via* several processes. They regulate blood glucose level through antioxidative effect, a crucial element in the onset and advancement of diabetes, through glucose and lipid metabolism regulation, and insulin resistance reduction [2, 9, 10]. This review provides an overview of medicinal plants with anti-diabetic properties. It focuses on phytochemicals identification, classification, and their biochemical and molecular mechanisms through which they exert the hypoglycemic effect.

2. METHODS

This review was conducted by performing a literature search of electronic databases: Scopus, Google Scholar, and ScienceDirect to collect relevant studies on the anti-diabetic potential of medicinal plants. Articles published between 2000 and 2025 were considered. The literature search used keywords such as “medicinal plants”, “anti-diabetic activity”, “phytochemicals”, “insulin signaling”, “ α -amylase inhibition”, “ α -glucosidase inhibition”, “*in vitro*”, “*in vivo*”, and “*in silico*”.

An initial search yielded 1,245 records. After removal of duplicates, 1,020 records were screened based on titles and abstracts. Selected papers were research articles or reviews that evaluated the anti-diabetic properties of medicinal plants or isolated phytochemicals. Only studies providing experimental evidence, such as *in vitro*, *in vivo*, or *in silico* approaches, were considered. These studies reported effects on glucose regulation, insulin signaling, enzyme inhibition (α -amylase, α -glucosidase), antioxidant

activity, or related metabolic markers. Studies were excluded if they lacked experimental or mechanistic evidence, were not directly related to diabetes or metabolic dysfunction, or focused on synthetic drugs without plant-based components. Following full-text evaluation, 54 articles were included in the final review, covering 16 medicinal plants with reported molecular anti-diabetic mechanisms (Fig. 1).




Fig. (1). Literature search and selection process for the review.

2.1. Study Selection Process

Full texts of potentially eligible studies were assessed independently by the authors based on the predefined inclusion and exclusion criteria. From the included studies, a total of sixteen medicinal plants traditionally used for diabetes management were identified and analyzed.

3. RESULTS AND DISCUSSION

3.1. Medicinal Plants with Antidiabetic Potential

Based on the literature search carried out through the databases Scopus, ScienceDirect, and Google Scholar, 16 plant species used in traditional medicine with an antidiabetic effect were identified. The medicinal plants discussed below were selected based on the availability of experimental evidence supporting their molecular anti-

diabetic effects. However, they differ in botanical origin and phytochemical composition. Many converge on common biological pathways relevant to glucose homeostasis, including inhibition of carbohydrate-digesting enzymes, modulation of insulin signaling, enhancement of glucose uptake, and attenuation of oxidative stress and inflammation. The medicinal plants

reviewed in this section are summarized in Table 1, which compares their major bioactive compounds, principal antidiabetic mechanisms, experimental models, and strength of evidence. Selected plants are discussed below to highlight representative mechanisms and supporting studies.

Table 1. Comparative summary of medicinal plants with antidiabetic potential, major bioactive compounds, molecular mechanisms, and level of experimental evidence.

Medicinal Plant	Major Bioactive Compounds	Main Molecular Mechanisms Related to Diabetes	Experimental Model	Evidence Level	References
<i>Arachis hypogaea</i> (L.) (peanut shells)	Luteolin, pyrogallol, catechol, quercetin, polyphenols	Antioxidant activity; inhibition of α -amylase and carbohydrate digestion	<i>In vitro</i>	Limited	[11, 12]
<i>Boswellia sacra</i> (Flueck.)	Boswellic acid derivatives	Reduction of blood glucose; modulation of inflammatory and metabolic pathways	<i>In vitro, in vivo & in silico</i>	Moderate	[13, 14]
<i>Berberis glaucocarpa</i> (Stapf)	Berberine, palmatine, dihydroberberine derivatives	Hypoglycemic effects: improvement of glucose metabolism and insulin sensitivity	<i>In vivo</i>	Moderate	[15, 16]
<i>Coccinia grandis</i> (L.) Voigt	Cephalandrine, taraxerol, β -sitosterol, lupeol	Reduction of blood glucose; modulation of lipid and glucose metabolism	<i>In vivo</i>	Moderate	[17, 18]
<i>Dittrichia viscosa</i> (L.)	Polyphenols	Inhibition of α -glucosidase and α -amylase; increased GLP-1 levels; reduced glucose absorption	<i>In vitro & in vivo</i>	Moderate	[19, 20]
<i>Gracilaria bursapastoris</i>	Diterpenes, phenolic acids, bromophenols	Antioxidant and anti-inflammatory effects; indirect glucose-lowering activity	<i>In vitro & in silico</i>	Limited	[21, 22]
<i>Gymnema sylvestre</i> (Retz.)	Gymnemic acids, stigmaterol, quercitol	Stimulation of insulin secretion; β -cell protection; enhanced glucose uptake	<i>In vitro & in silico</i>	Strong	[23, 24]
<i>Opilia acuminata</i> Wall. ex Baill.	Kaempferol	Insulin secretion, increased cellular glucose uptake, and antioxidant effects	<i>In vitro & in silico</i>	Limited	[25, 26]
<i>Xenostegia tridentata</i> (L.)	Alkaloids, luteolin, and diosmetin derivatives	Hypoglycemic activity; modulation of carbohydrate metabolism	<i>In vitro & in vivo</i>	Moderate	[27, 28]
<i>Morus alba</i> (L.)	Rutin, quercetin-3-O- β -D-glucoside	Activation of AMPK; Akt-mediated insulin signaling; enhanced glucose uptake	<i>In vitro, in vivo & in silico</i>	Strong	[29, 30]
<i>Phellinus igniarius</i> (L.)	Styrylpyrones (phenolics)	Inhibition of α -glucosidase; suppression of protein glycation and oxidative stress	<i>In vitro, in vivo & in silico</i>	Moderate	[31-34]
<i>Punica granatum</i> (L.)	Phenols, tannins, triterpenoids	Reduction of blood glucose; antioxidant and anti-inflammatory mechanisms	<i>In vitro & in vivo</i>	Strong	[35, 36]
Red ginseng (<i>Panax ginseng</i> C.A. Meyer)	Ginsenosides (saponins), volatile oils	Improved insulin sensitivity; enhanced insulin signaling; increased fatty acid oxidation	<i>In vitro, in vivo & in silico</i>	Strong	[37, 38]
<i>Saccharum officinarum</i> (L.)	Tricin, apigenin, naringenin, and luteolin derivatives	Antioxidant and anti-inflammatory effects; indirect metabolic regulation	<i>In vitro</i>	Limited	[39, 40]
<i>Vernonia amygdalina</i> (Delile.)	Sesquiterpene lactones, flavonoids, saponins	Hypoglycemic and antioxidant effects.	<i>In vivo</i>	Moderate	[41, 42]
<i>Wisteria sinensis</i> (Sims) Sweet	Flavonoids (luteolin, apigenin derivatives), saponins	Activation of IRS-1/PI3K/Akt/GLUT4 pathway; improved glucose uptake	<i>In vitro & in vivo</i>	Moderate	[43-45]

Arachis hypogea (L.) (Peanut shells) are abundant in polyphenols, luteolin, carotene, and iso-saponaretin [11]. Polyphenol-rich extracts from peanut shells exhibit antidiabetic activity primarily via antioxidant effects and inhibition of carbohydrate-hydrolyzing enzymes such as α -amylase; however, direct evidence linking these effects to insulin signaling or glucose uptake pathways remains limited. HPLC characterization revealed the presence of luteolin at the highest amount, followed by pyrogallol, catechol, phlorglucinol, and quercetin, which are responsible for the therapeutic effect [11, 12].

Boswellia sacra (Flueck.), which belongs to the Burseraceae family, generates aromatic oleo-gum resin, commonly referred to as frankincense, which traditionally stands out for medicinal purposes [13]. Studies reported active boswellic acid derivatives as the anti-diabetic agent of the plant, which lower blood glucose via several mechanisms of action [14].

Berberis glaucocarpa (Stapf), belonging to the Berberidaceae family, is widely distributed worldwide. Its root decoction is traditionally used for the treatment of diabetes [15]. Berberin, palmatine, and 8-trichloromethyl dihydroberberine are the plant's major compounds that confer its hypoglycemic activity [16].

Coccinia grandis (L.) Voigt belongs to the Cucurbitaceae family, native to the tropical areas of Asia, and plays a significant role in traditional medicine as a complementary therapy for diabetes mellitus management [17]. Phytochemical characterization revealed the presence of cephalandrine a, cephalandrine b, taraxerol, stigmast-7-en-3-one cephalandrol, β -sitosterol, lupeol, taraxerone, and tritriacontane, responsible for the hypoglycemic effect [18].

Dictyria viscosa (L.) (Inula viscosa (L.) Aiton) is mainly distributed in Africa, Asia, and Europe. It is traditionally used for wound healing, rheumatic pain, and treatment of bronchitis and tuberculosis [19]. Its abundance in polyphenols contributes to anti-diabetic effects via: inhibition of glucose absorption in the intestine through inhibiting β -glucosidase and α -amylase activity, and increasing glucagon-like peptide 1 (GLP1) [20].

Gracilaria bursa-pastoris, a red macroalga primarily known for its culinary use rather than its medicinal properties, is distributed across temperate and tropical regions of the northeast Atlantic and the Mediterranean. [21]. It is composed of a variety of biologically active secondary metabolites: diterpenes, phenolic acids, sulfonic acids, bromophenols, heterosides, etc., which possess anti-diabetic, antioxidant, and anti-inflammatory activities [22].

Gymnema sylvestre (Retz.), commonly known as "Gurmar," belongs to the family Asclepiadaceae; it is one of the most popular anti-diabetic plants, distributed in Asia, tropical Africa, Malaysia, and Sri Lanka [23]. It exhibits glucose absorption modulation, stimulates insulin secretion, and promotes β -cell regeneration. *Gymnema sylvestre* represents one of the most extensively studied and mechanistically supported anti-diabetic medicinal plants [24].

Opilia acuminata Wall. ex Baill., belongs to the family Opiliaceae; it is cultivated and used to treat diabetes in Yunnan, Indonesia, Malaysia, Thailand, and Vietnam [25]. Numerous bioactive constituents were identified in it. Among them, kaempferol (its predominant compound) plays a key role by stimulating insulin release, promoting cellular glucose uptake, and mitigating oxidative stress [26].

Despite their diverse botanical origins, the reviewed species converge on a limited number of antidiabetic mechanisms, mainly insulin signaling modulation, inhibition of carbohydrate-digesting enzymes, and oxidative stress attenuation (Table 1). However, the strength of evidence differs substantially, with several plants supported mainly by *in vitro* or *in silico* data.

Xenostegia tridentata (L.) belongs to the family Convolvulaceae, is distributed in different parts of the world, and is used for the treatment of different disorders: swellings, rheumatism, urinary infections, and its root extracts are beneficial in the treatment of diabetes [27]. Several studies highlighted the abundance of bioactive components: alkaloids, luteolin-7-O- β -D-glucoside, diosmetin, diosmetin-7-O- β -D-glucoside, and luteolin, responsible for the anti-diabetic effect [28].

Morus alba (L.) (Moraceae), commonly known as the white mulberry tree, is native to Europe and Asia. Traditionally, it has been used to prevent various disorders and to help manage elevated blood glucose levels [29]. Phytochemical studies have identified two major compounds, rutin and quercetin-3-O- β -D-glucoside (Q3G), which enhance glucose uptake through the Akt-mediated insulin signaling pathway and activation of AMP-Activated Protein Kinase (AMPK) [30]. These findings place *Morus alba* among plants with robust molecular evidence targeting key regulators of glucose metabolism.

Phellinus igniarius (L.), commonly referred to as "Sanghuang", has been used in oriental countries for the treatment of various diseases [31]. It is a fungus, well-known for its numerous therapeutic effects, including anti-diabetic and anti-inflammatory properties [33]. Characterization studies revealed that styrylpyrones (phenol components) from *Phellinus* species have multi-target anti-diabetic effects via: inhibition of α -glucosidase, protein glycation, and oxidative stress [32-34].

Punica granatum (L.) is a member of the Puniceae family. It has been used in folk medicine for centuries in the Mediterranean region, the Middle East, India, and China [35]. Traditionally, it has been employed to alleviate conditions ranging from inflammation and rheumatism to mild throat pain. Its flowers have been used as an antidiabetic medicine as they can significantly lower the blood glucose level via different mechanisms due to their high content of phenols, tannins, and triterpenoids [36].

Red ginseng (steamed and dried form of *Panax ginseng* C.A. Meyer) is commonly used in Asian folk medicine for its various biological activities, especially antidiabetic properties [37]. It mainly contains saponins and volatile oils that improve insulin sensitivity, enhance insulin signal transduction, and promote fatty acid oxidation [38].

Saccharum officinarum (L.), known as sugarcane, native to south and southeastern Asia [39], is rich in phytochemicals such as flavonoids, stilbenes, phenolic acids, tannins, and lignans. Key phenolics, including tricetin, apigenin, naringenin, and luteolin derivatives, exhibit antitumor, anti-inflammatory, antioxidant, and antihistamine activities [40].

Vernonia amygdalina (Delile.), belonging to the Asteraceae family, is one of the most popularly used in traditional medicine in Africa and Asia. Leaves and roots decoctions have been used to treat kidney problems, hiccups, fevers, stomach disorders, and diabetes [41]. Several studies reported active phytochemicals, including: terpenes, alkaloids, saponins, tannins, flavonoids, phenolics, steroidal glycosides, triterpenoids, and several types of sesquiterpene lactones that are responsible for the anti-diabetic activity [42].

Wisteria sinensis (Sims) Sweet (known as Chinese wisteria) belongs to the Leguminosae family and is widely abundant in Asian countries. It is commonly used in the treatment of stomach ulcers, cancers, and inflammatory rheumatism [43]. Its secondary metabolites, polyphenols, triterpenes, saponins, isoflavones, and lectins, give the plant strong antioxidant, antimicrobial, anti-inflammatory, and antitumoral properties [45]. The high content of flavonoids: luteolin-7-O- β -D-glucoside, apigenin 4'-O- β -D-glucopyranoside, apigenin-7-(6''-acetyl-glucopyranoside), luteolin, and apigenin gives a beneficial hypoglycemic effect, alleviating type 2 diabetes via activation of IRS-1/PI3K/Akt/GLUT4 pathway [44].

Among the surveyed species, *Gymnema sylvestris*, *Morus alba*, *Panax ginseng* (red ginseng), and *Punica granatum* exhibit the strongest mechanistic support, supported by multiple *in vitro* and *in vivo* studies. Plants such as *Dittrichia viscosa*, *Phellinus igniarius*, and *Wisteria sinensis* display moderate mechanistic evidence. In contrast, species including *Arachis hypogaea* shells, *Gracilaria bursa-pastoris*, *Opilia acuminata*, and *Saccharum officinarum* are supported mainly by biochemical, antioxidant, or preliminary cellular assays, with limited direct validation of their molecular targets in diabetic models. However, contradictory findings regarding bioavailability, dose-dependence, and insulin secretagogue activity remain for several species, underscoring the need for standardized experimental designs and clinical validation. For most of the medicinal plants reviewed, clinical studies are currently lacking. Thus, the translational relevance of preclinical findings remains uncertain, and well-designed human trials are necessary.

Despite the apparent convergence toward common molecular targets, the strength of evidence varies considerably among the reviewed plants. Species classified as having strong evidence, such as *Gymnema sylvestris*, *Morus alba*, *Panax ginseng*, and *Punica granatum*, are supported by multiple *in vivo* studies and mechanistic investigations. In contrast, plants with limited evidence rely predominantly on *in vitro* enzymatic inhibition or antioxidant assays, which do not fully reflect

the complexity of glucose homeostasis *in vivo*. Moreover, differences in extraction procedures, phytochemical standardization, and experimental models limit direct comparison between studies and may partly explain discrepancies in reported efficacy. The convergence of anti-diabetic mechanisms observed among the reviewed medicinal plants can be largely attributed to a set of recurrent bioactive phytochemicals. Identifying these compounds and elucidating their molecular actions is essential. Thus, attention is next directed toward the phytochemicals responsible for anti-diabetic effects. The subsequent subsection discusses their molecular mechanisms of action in diabetes mellitus.

3.2. Bioactive Phytochemicals' Effects on Diabetes Mellitus

Diabetes Mellitus (DM) is characterized by increased levels of blood sugar (glucose) above the physiological range, due to insufficient insulin activity and/ or secretion [28]. Its etiology varies, leading to different types: type 1 diabetes (an autoimmune condition causing beta-cell death), type 2 diabetes (the most prevalent type characterized by insulin resistance), gestational diabetes (may be developed during pregnancy), and other types of diabetes (caused by genetic defects in beta-cell function, pancreatic disorders, or associated with endocrinopathies) [3, 6]. Many plants have been used as folk medicine to ameliorate diabetes patients' conditions, without side effects and via several mechanisms of action [46]. Various plant compounds and their molecular antidiabetic effects are reported in this part.

3.2.1. GLUT Transport and Insulin Pathway Modulation

Numerous studies have been conducted on the modulation of glucose transporters (GLUT) activities, transmembrane proteins responsible for glucose uptake via insulin-stimulated transport into skeletal muscle and adipose tissue [47, 48]. An *in vivo* results study reported a great hypoglycemic activity of *Wisteria sinensis* flowers' extract, lowering blood glucose [44]. The mechanism of action was explored by an *in vitro* investigation. Western blot results showed that this extract significantly decreased IRS-1 phosphorylation, enhancing PI3K expression, elevating Akt phosphorylation and GLUT4 expression and its translocation into the plasma membrane of L6 cells, inducing glucose uptake in liver and skeletal muscle, thus contributing to hyperglycemia reduction [44]. GLUT1 expression was also enhanced in both the transcription and translation levels in the presence of *Chimonanthus nitens* leaf extract [49]. A relevant study showed the hypoglycemic effect of Peanut Shell Polyphenol Extract (PSPE). The treatment reversed the defective glycogen storage in the diabetic state, probably via the promotion of GLUT1 for glucose absorption into the hepatic tissues and its conversion into glycogen [12]. Another *in vivo* study on a type 2 diabetic mouse model demonstrated the anti-diabetic activity of *Phellinus igniarius* (L.) polyphenol-rich extract (PI-PRE), which displayed, after a 4-week treatment, a stimulatory

effect on GLUT4 expression and translocation, alongside this, p-AMPK α /AMPK ratio up-regulation, analyzed by western blotting, leading to glucose uptake [50]. A different investigation also revealed the modulation effect of *Punica granatum* flower polyphenols extract (PGF) on the insulin pathway. Western blotting of markers from the liver tissue obtained after the *in vivo* study showed enhanced phosphorylation of IR, Akt, and GSK-3 β , leading to improved insulin signaling activity, thus, to glucose uptake and an increase of glycogen content [35]. A further study provided evidence on the anti-diabetic effect of *L. sylvestris* extract evaluated *in vitro*, where isolated compounds: Interruptin A, interruptin C, ergosterol, and diglycerol promoted insulin secretion from beta cells of the INS-1E cell line [26]. A similar investigation on the effect of Polyphenol-Rich Sugarcane Extract (PRSE) on glucose uptake in the Caco-2 cells line (which mimics the human intestinal cells in sugar absorption capacity) demonstrated an inhibition of intestinal glucose absorption by affecting both facilitated diffusion and active transport mechanisms, also inhibiting cellular production of GLUT2, thus, intestinal sugar uptake [39]. Similar findings were reported by another study [18]. New evidence from another investigation reported the antidiabetic effect of rutin and Q3G isolated from the fruits of *Morus alba*, on 3T3-L1 adipocytes cell line, results revealed that these two compounds improved glucose uptake by a simultaneous

activation of AMPK (Akt phosphorylation) and the insulin signaling pathway [30]. Figure 2 below summarizes these activities. While activation of the PI3K/Akt/GLUT axis appears as a recurrent mechanism across multiple plant extracts, most evidence is derived from cell-based models such as L6, 3T3-L1, and HepG2 cells. These systems do not fully reproduce insulin resistance or metabolic regulation observed in human type 2 diabetes. Furthermore, differences in extract composition and concentrations used across studies make it difficult to determine whether the observed effects result from direct insulin mimetic activity or secondary metabolic adaptations.

3.2.2. Blood Glucose Level Modulation

Several studies explored the modulating effect of plant extracts on blood glucose release and uptake. A relevant study demonstrated *in vitro* and *in silico* potent inhibitory activity of quercetin and kaempferol, identified from *Gymnema sylvestre* leaves extract, against α -amylase enzyme. Additionally, a stable and precise interaction of rutin within the active site of peroxisome proliferator-activated receptor-gamma (PPAR γ) protein, exhibiting an agonist effect, which improves the glucose-sensing abilities of pancreatic β -cells and insulin sensitivity, thus enhancing glucose uptake [24]. The hypoglycemic effect of different *Gracilaria bursa-pastoris* extracts (hexane, ethyl acetate, methanol, and water extracts) was revealed via




Fig. (2). Insulin and GLUT pathways modulation of different medicinal plant extracts. It illustrates the modulation of insulin signaling and glucose transport by polyphenol-rich extracts from *Wisteria sinensis*, *Punica granatum*, *Phellinus igniarius*, and *Saccharum officinarum*. AMPK and PI3K/Akt pathways are consistently activated across multiple plants, leading to GLUT translocation and enhanced glucose uptake in liver, muscle, and adipose tissue.

in vitro inhibitory activities on pancreatic α -amylase and α -glucosidase enzymes. Molecular docking showed that rutin formed a stable and favorable interaction with the α -amylase active site [21]. Another *in vivo* study conducted on alloxan-induced diabetic mice showed that the flavonoids: cymaroside and cosmosiin present in *Xenostegia tridentata* (L.) stem and roots' water and ethanol extracts have strong hypoglycemic activities. *In vitro* assay proved that the extracts exhibited inhibitory effects on key enzymes (α -amylase and α -glucosidase) that play an important role in hydrolyzing glycosidic bonds [28]. The *in-silico* part revealed that cymaroside and cosmosiin had the greatest binding affinity with α -amylase and α -glucosidase, thus, helping in the decrease of glucose absorption in the intestines, delaying its liberation into the bloodstream. They also had the best dock conformation with glycogen phosphorylase (GP) receptor, inducing glycogenolysis inhibition, thus, reducing hepatic glucose production and lowering blood glucose; moreover, quercetin had the best binding affinity with PPAR- γ , it established four bonds with ASP260, and SER342 amino acids. Thus, could facilitate fatty acid uptake into adipocytes and the transfer of lipids from non-adipose to adipose tissues [28]. The anti- α -glucosidase activity of *Opilia acuminata* leaf extract was confirmed through *in vitro* and *in silico* studies. Interruption C and the novel diterpene compounds uncompetitively bind to HIS 280 in the enzyme's catalytic pocket, inhibiting its activity [26]. However, inhibition of α -amylase and α -glucosidase, while effective in reducing postprandial hyperglycemia, is associated with gastrointestinal side effects and may offer limited benefit as a standalone strategy. Moreover, many conclusions in this category are based on molecular docking and *in vitro* enzyme inhibition, which do not account for bioavailability, intestinal metabolism, or compound stability under physiological conditions [24]. Other studies also showed the *in vivo* anti-diabetic effect of Peanut shell polyphenol extract (PSPE) and *Punica granatum* flower polyphenols extract (PGF). The oral glucose tolerance test results indicated that after PSPE and PGF treatments, an improvement in glucose intolerance in diabetic rats was observed by decreasing blood glucose compared to the diabetic control group [12, 35]. A different study reported the effect of Polyphenol-Rich Sugarcane Extract (PRSE) on the restoration of insulin production in dysfunctional β -cells. The *in vitro* treatment of glucotoxic-induced insulin-dysfunctional rat pancreatic β -cell model was able to restore insulin production by 39.48%, which is a great approach for type 2 diabetic treatment [39]. Another *in vivo* study demonstrated the anti-diabetic effect of *Dittrichia viscosa* on STZ-induced diabetes in rats. Besides lowering blood sugar measured by a colorimetric method, phosphoenolpyruvate carboxykinase (PEPCK), a crucial enzyme at the early step of the gluconeogenic pathway, was also reduced when treated with gold nanoparticles of *D. viscosa* (AuNPs). Even its mRNA expression levels were decreased, leading to insulin secretion enhancement, thus to glucose uptake and hypoglycemic effect [20]. All these therapeutic activities are regrouped in Fig. (3).

3.2.3. Reactive Oxygen Species (ROS) Production Modulation

The pathophysiology of diabetes has been linked to oxidative stress either as a causative factor or because of its consequences; it contributes to cellular structural abnormality of the liver, kidney, and pancreas [51]. An *in vivo* investigation showed that pomegranate (*Punica granatum* L.) peel extract (PPE), combined with L-carnitine, treated mice for 12 weeks, restored the antioxidant enzyme "nuclear factor erythroid 2-related factor 2" (Nrf2) activity after induced diabetes. It also enhanced the activity of antioxidant enzymes (catalase (CAT) and superoxide dismutase (SOD)), thus downregulated the hyperglycemia through the antioxidant system [52]. An additional *in vivo* study supported the anti-hyperglycemic effects of PSPE *via* antioxidant activity, restoring SOD, Glutathione (GSH), and Malondialdehyde (MDA) hepatic levels, thus reversing pathological changes in the pancreatic islets, improving cellular structures [12]. Similar *in vivo* results of CAT, SOD, and glutathione peroxidase (GPx) levels restoration were revealed, supporting the anti-diabetic effect of PGF *via* oxidative stress regulation [35]. Consistent with the mechanisms described above, the polyphenol-rich *Vernonia amygdalina* leaves extract expressed similar results, where pancreatic SOD, CAT, and GPx activities were enhanced. In addition, GSH level was restored [42]. This was also seen in another investigation, which examined the *in vivo* antidiabetic effects of palmatine, berberine, and 8-trichloromethyl dihydroberberine derived from *Berberis glaucocarpa*. It enhanced SOD and CAT antioxidant enzyme levels [16]. Another subsequent research result revealed that red ginseng extract regulates oxidative stress, *via* an upregulation of LysoPCs and LysoPEs phospholipids (metabolites of glycerol-phospholipids), regulating the metabolism disorder, the oxidative state, and improving islet tissue damage [38]. An additional report on the anti-diabetic effect of β -Boswellic acid (β -BA) and 11-keto- β -boswellic acid (β -KBA) isolated from *B. sacra*, *in vivo* treatment on streptozotocin (STZ)-induced diabetic rats showed a restoration of oxidative state balance. It reduced plasma MDA (inhibiting lipid peroxidation) and increased SOD antioxidant enzyme activity. Alongside this, it demonstrated a reversal of the pathological alterations in pancreas and kidney histological architectures [14]. These effects are summarized in Fig. (4). Although antioxidant activity is consistently reported across many plants, oxidative stress modulation alone may not be sufficient to achieve sustained glycemic control. In several studies, improvements in antioxidant markers were not systematically correlated with insulin sensitivity or glucose uptake, highlighting the need to distinguish between supportive cytoprotective effects and direct antidiabetic mechanisms.

It is important to note the limitations in translational relevance. The majority of evidence is derived from *in vitro*, *in vivo*, or *in silico* studies, and no clinical trials are available to confirm efficacy in humans. Furthermore, factors such as bioavailability, pharmacokinetics, and

metabolic stability of phytochemicals can significantly influence therapeutic outcomes. Effective concentrations observed in experimental studies may not be achievable through conventional dosing of plant extracts. In addition, variability in plant composition due to species differences, extraction methods, and environmental conditions may affect the reproducibility and reliability of results. These limitations underscore the need for carefully

designed clinical studies and standardization of extracts before medicinal plants or isolated phytochemicals can be reliably translated into safe and effective anti-diabetic therapies. Additionally, future studies should integrate standardized extract characterization, dose-response analyses, and combined pharmacokinetic-pharmacodynamic evaluations to better correlate molecular mechanisms with therapeutic efficacy.




Fig. (3). Phytochemicals' potential on carbohydrate digestion enzymes and gluconeogenesis inhibition. This figure summarizes the effect of *Gymnema sylvestre*, *Dittrichia viscosa*, *Xenostegia tridentata*, *Opilia acuminata*, and *Gracilaria bursa-pastoris* extracts on insulin secretion, α -amylase/ α -glucosidase inhibition, and glycogen metabolism. Activation of PPAR- γ , inhibition of α -amylase/ α -glucosidase, and glycogen phosphorylase suppression are observed across several species, promoting insulin secretion and lowering blood glucose.




Fig. (4). Key roles of phytochemicals from different medicinal plants in ROS scavenging activities for anti-diabetic effect. It illustrates the antioxidant and cytoprotective mechanisms of *Arachis hypogaea*, *Punica granatum*, and *Berberis glaucocarpa* extracts. These plants reduce ROS and lipid peroxidation, enhance SOD, CAT, and GPx activity, and protect pancreatic β -cells, liver, and kidney from apoptosis. ROS scavenging and antioxidant enzyme activation appear as consistent protective mechanisms across these species.

CONCLUSION

This review highlights the molecular anti-diabetic potential of sixteen medicinal plants traditionally used for diabetes management, demonstrating that their efficacy largely converges on a limited number of core biological pathways. Across the surveyed literature, plant-derived phytochemicals, particularly flavonoids, alkaloids, and polyphenols, consistently modulate insulin signaling cascades, including IRS-1/PI3K/Akt and AMPK pathways, promote GLUT4-mediated glucose uptake, inhibit carbohydrate-digesting enzymes (α -amylase and α -glucosidase), and attenuate oxidative stress. Collectively, these mechanisms support their hypoglycemic effects and their relevance to type 2 diabetes pathophysiology.

Despite this promising mechanistic evidence, most data remain derived from *in vitro*, *in vivo*, or *in silico* studies. Important translational challenges persist, including limited information on bioavailability, dose-response relationships, long-term safety, and variability in phytochemical composition among crude extracts. In addition, discrepancies in experimental models and methodologies complicate direct comparison across studies and hinder clinical extrapolation.

Future research should prioritize the standardization of plant extracts, detailed pharmacokinetic and toxicological evaluation of key bioactive compounds, and well-designed clinical trials to validate therapeutic efficacy. Addressing these gaps will be essential for

translating molecular insights into evidence-based, plant-derived interventions that may serve as effective adjuncts or alternatives in diabetes management.

AUTHORS' CONTRIBUTIONS

The authors confirm their contributions to the paper as follows: S.O.: Article analysis and drafting of the original manuscript; M.T.: Conceptualization and drafting of the original manuscript; N.Be., L.A. and N.Br.: Supervised the writing and editing process. All authors read and approved the final manuscript.

LIST OF ABBREVIATIONS

AMPK	= AMP-activated protein kinase
Akt	= protein kinase B
AuNPs	= gold nanoparticles
CAT	= catalase
GLUT	= glucose transporter
GLUT2	= glucose transporter type 2
GLUT4	= glucose transporter type 4
GP	= glycogen phosphorylase
GPx	= glutathione peroxidase
GLP-1	= glucagon-like peptide-1
GSH	= glutathione

GSK-3 β = glycogen synthase kinase-3 beta
 INS-1E = rat pancreatic beta-cell line
 IR = insulin receptor
 IRS-1 = insulin receptor substrate-1
 L6 = rat skeletal muscle cell line
 LysoPCs = lysophosphatidyl cholines
 LysoPEs = lysophosphatidyl ethanol amines
 MDA = malondialdehyde
 Nrf2 = nuclear factor erythroid 2-related factor 2
 PEPCK = phosphoenolpyruvate carboxykinase
 PGF = Punica granatum flower polyphenols extract
 PI3K = phosphoinositide 3-kinase
 PPAR- γ = peroxisome proliferator-activated receptor gamma
 PRSE = polyphenol-rich sugarcane extract
 PSPE = peanut shell polyphenol extract
 Q3G = quercetin-3-O- β -D-glucoside
 ROS = reactive oxygen species
 SOD = superoxide dismutase
 STZ = streptozotocin
 β -BA = β -boswellic acid
 β -KBA = 11-keto- β -boswellic acid

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

Maria Trapali is an Associate Editorial Board Member of The Open Biochemistry Journal.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1] Lagouri, V.; Tebbi, S.O.; Caseiro, A.; Trapali, M. Lamiaceae family plants as natural solutions for inflammation and blood sugar management. *Eur. Sci. J.*, **2024**, *20*(30), 34-34. <http://dx.doi.org/10.19044/esj.2024.v20n30p34>
- [2] Uti, D. E.; Atangwho, I. J.; Alum, E. U.; Egba, S. I.; Ugwu, O. P.-C.; Ikechukwu, G. C. Natural antidiabetic agents: Current evidence and development pathways from medicinal plants to clinical use. *Nat. Prod. Commun.*, **2025**, *20*(3), 1934578X251323393. <http://dx.doi.org/10.1177/1934578X251323393>
- [3] Khanam, S. Antidiabetic agents produced from medicinal and aromatic plants. In: *Herbal Medicine: A Benign and Conventional Medical System*; Immortal Publications, **2021**; p. 67.
- [4] Kooti, W.; Farokhipour, M.; Asadzadeh, Z.; Ashtary-Larky, D.; Asadi-Samani, M. The role of medicinal plants in the treatment of diabetes: A systematic review. *Electron. Physician*, **2016**, *8*(1), 1832-1842.

- [5] Tebbi, S.O.; Trapali, M.; Letsiou, S. Exploring the anti-diabetic, antioxidant and anti-microbial properties of *Clematis flammula* L. Leaves and *Pistacia lentiscus* L. fruits using choline chloride-based deep eutectic solvent. *Waste Biomass Valoriz.*, **2024**, *15*(5), 2869-2879. <http://dx.doi.org/10.1007/s12649-023-02360-9>
- [6] Alam, S.; Sarker, M.M.R.; Sultana, T.N.; Chowdhury, M.N.R.; Rashid, M.A.; Chaity, N.I.; Zhao, C.; Xiao, J.; Hafez, E.E.; Khan, S.A.; Mohamed, I.N. Antidiabetic phytochemicals from medicinal plants: Prospective candidates for new drug discovery and development. *Front. Endocrinol.*, **2022**, *13*, 800714. <http://dx.doi.org/10.3389/fendo.2022.800714> PMID: 35282429
- [7] George, C.; Echouffo-Tcheugui, J.B.; Jaar, B.G.; Okpechi, I.G.; Kengne, A.P. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries - A review of the current literature. *BMC Med.*, **2022**, *20*(1), 247. <http://dx.doi.org/10.1186/s12916-022-02438-6> PMID: 35915501
- [8] Cherrada, N.; Elkhalfa Chems, A.; Gheraissa, N.; Zaater, A.; Benamor, B.; Ghania, A.; Yassine, B.; Kaddour, A.; Afzaal, M.; Asghar, A.; Saeed, F.; Teferi Asres, D. Antidiabetic medicinal plants from the Chenopodiaceae family: A comprehensive overview. *Int. J. Food Prop.*, **2024**, *27*(1), 194-213. <http://dx.doi.org/10.1080/10942912.2023.2301576>
- [9] Trapali, M.; Tebbi, S.O.; Karkalousos, P.; Debbache-Benaida, N.; Chaniotis, D.; Apostolopoulos, V. Antioxidant and antidiabetic potential of *Acanthus mollis* L. using choline chloride-based deep eutectic solvents. *Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed.*, **2024**, *38*(1), 19-25. <http://dx.doi.org/10.61873/OJFV6764>
- [10] Yi, X.; Dong, M.; Guo, N.; Tian, J.; Lei, P.; Wang, S.; Yang, Y.; Shi, Y. Flavonoids improve type 2 diabetes mellitus and its complications: A review. *Front. Nutr.*, **2023**, *10*, 1192131. <http://dx.doi.org/10.3389/fnut.2023.1192131> PMID: 37324738
- [11] Gao, F.; Ye, H.; Yu, Y.; Zhang, T.; Deng, X. Lack of toxicological effect through mutagenicity test of polyphenol extracts from peanut shells. *Food Chem.*, **2011**, *129*(3), 920-924. <http://dx.doi.org/10.1016/j.foodchem.2011.05.046> PMID: 25212319
- [12] Sun, X.; Ye, H.; Liu, J.; Wu, L.; Lin, D.; Yu, Y.; Gao, F. Assessment of anti-diabetic activity of peanut shell polyphenol extracts. *J. Zhejiang Univ. Sci. B*, **2018**, *19*(10), 764-775. <http://dx.doi.org/10.1631/jzus.B1700401> PMID: 30269444
- [13] Khan, F.; Rashaan, L. Phytochemical analysis and pharmaceutical applications of monoterpenoids present in the essential oil of *Boswellia sacra* (Omani Luban). *Adv. Pharmacol. Pharm. Sci.*, **2025**, *2025*(1), 3536898. <http://dx.doi.org/10.1155/adpp/3536898> PMID: 40040632
- [14] Khan, A.; Khan, I.; Halim, S.A.; Rehman, N.U.; Karim, N.; Ahmad, W.; Khan, M.; Csuk, R.; Al-Harrasi, A. Anti-diabetic potential of β -boswellic acid and 11-keto- β -boswellic acid: Mechanistic insights from computational and biochemical approaches. *Biomed. Pharmacother.*, **2022**, *147*, 112669. <http://dx.doi.org/10.1016/j.biopha.2022.112669> PMID: 35121344
- [15] Belwal, T.; Bisht, A.; Devkota, H.P.; Ullah, H.; Khan, H.; Pandey, A.; Bhatt, I.D.; Echeverría, J. Phytopharmacology and clinical updates of *Berberis* species against diabetes and other metabolic diseases. *Front. Pharmacol.*, **2020**, *11*, 41. <http://dx.doi.org/10.3389/fphar.2020.00041> PMID: 32132921
- [16] Alamzeb, M.; Shah, S.W.A.; Hussain, H.; Zahoor, M.; Ahmad, S.; Mughal, E.U.; Ahmad, S.; Ullah, I.; Khan, S.; Ullah, A.; Ghias, M.; Ullah, R.; Ali, E.A. Beneficial effects of natural alkaloids from *Berberis glaucocarpa* as antidiabetic agents: An *in vitro*, *in silico*, and *in vivo* approach. *ACS Omega*, **2024**, *9*(8), 9813-9822. <http://dx.doi.org/10.1021/acsomega.3c10232> PMID: 38434828
- [17] Phimarn, W.; Taengthonglang, C.; Sungthong, B. Efficacy and safety of *Coccinia grandis* (L.) Voigt on blood glucose and lipid profile: An updated systematic review and meta-analysis. *J.*

- Herbmed Pharmacol.*, **2024**, 13(3), 342-352.
<http://dx.doi.org/10.34172/jhp.2024.49331>
- [18] Putra, I. M. W. A.; Fakhruddin, N.; Nurrochmad, A.; Wahyuono, S. Antidiabetic activity of *Coccinia grandis* (L.) Voigt: Bioactive constituents, mechanisms of action, and synergistic effects. *J. Appl. Pharm. Sci.*, **2021**, 12(1), 41-54.
<http://dx.doi.org/10.7324/JAPS.2021.120103>
- [19] Ouari, S.; Benzidane, N. Chemical composition, biological activities, and molecular mechanism of *Inula viscosa* (L.) bioactive compounds: A review. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **2024**, 397(6), 3857-3865.
<http://dx.doi.org/10.1007/s00210-023-02930-7> PMID: 38180555
- [20] Ayyoub, S.; Al-Trad, B.; Aljabali, A.A.A.; Alshaer, W.; Al Zoubi, M.; Omari, S.; Fayyad, D.; Tambuwala, M.M. Biosynthesis of gold nanoparticles using leaf extract of *Dittrichia viscosa* and *in vivo* assessment of its anti-diabetic efficacy. *Drug Deliv. Transl. Res.*, **2022**, 12(12), 2993-2999.
<http://dx.doi.org/10.1007/s13346-022-01163-0> PMID: 35499716
- [21] Ouahabi, S.; Loukili, E.H.; Daoudi, N.E.; Chebaibi, M.; Ramdani, M.; Rahhou, L.; Bnouham, M.; Fauconnier, M.L.; Hammouti, B.; Rhazi, L.; Ayerdi Gotor, A.; Dépeint, F.; Ramdani, M. Study of the phytochemical composition, antioxidant properties, and *in vitro* anti-diabetic efficacy of *Gracilaria bursa-pastoris* extracts. *Mar. Drugs*, **2023**, 21(7), 372.
<http://dx.doi.org/10.3390/md21070372> PMID: 37504903
- [22] Rani, A.; Saini, K.C.; Fartyal, M.; Jaitak, V.; Bast, F. A concise review on the bioactive potential of the genus *Gracilaria* (Rhodophyta). *Nucleus*, **2025**, 68(1), 161-177.
<http://dx.doi.org/10.1007/s13237-024-00471-9>
- [23] Triveni, K.B.; Lakshmi, V.K.; Shashidhara, S.; Anitha, S. *Gymnema sylvestre*: A comprehensive review. *Pharma Sci. Mon.*, **2012**, 3(4), 2402-2420.
<http://dx.doi.org/10.5958/2231-5713.2020.00036.7>
- [24] Dar, M.I.; Sultan, A.; Abass, S.; Dev, K.; Parveen, R.; Ahmad, S.; Qureshi, M.I. Exploring the anti-diabetic mechanism of selective phytochemicals identified from *Gymnema sylvestre* using TLC-UPLC-MS, complemented by *in silico* studies. *Phytomedicine Plus*, **2024**, 4(3), 100606.
<http://dx.doi.org/10.1016/j.phyplu.2024.100606>
- [25] Ralte, L.; Sailo, H.; Kumar, N.S.; Singh, Y.T. Exploring the pharmacological potential of *Lepionurus sylvestris* blume: From folklore medicinal usage to modern drug development strategies using *in vitro* and *in silico* analyses. *BMC Complement. Med. Ther.*, **2024**, 24(1), 289.
<http://dx.doi.org/10.1186/s12906-024-04567-2> PMID: 39080609
- [26] Phooha, S.; Sangkaew, S.; Wattanapiromsakul, C.; Nuankaew, W.; Kang, T.H.; Dej-adisai, S. Phytochemical investigation of *Lepionurus sylvestris* blume and their anti-diabetes effects via anti-alpha glucosidase and insulin secretagogue activities plus molecular docking. *Pharmaceuticals*, **2023**, 16(8), 1132.
<http://dx.doi.org/10.3390/ph16081132> PMID: 37631052
- [27] Sabu, J.A.; Brijithlal, N.D. The pharmacological aspects of *Merremia tridentata*: A comprehensive review. *J. Indian Bot. Soc.*, **2024**, 104(1), 50-53.
<http://dx.doi.org/10.61289/jibs2024.11.15.1180>
- [28] Vo Van, L.; Pham, E.C.; Nguyen, C.V.; Duong, N.T.N.; Vi Le Thi, T.; Truong, T.N. *In vitro* and *in vivo* antidiabetic activity, isolation of flavonoids, and *in silico* molecular docking of stem extract of *Merremia tridentata* (L.). *Biomed. Pharmacother.*, **2022**, 146, 112611.
<http://dx.doi.org/10.1016/j.biopha.2021.112611> PMID: 35062075
- [29] Song, J.; Lee, D.; Lee, S.; Yu, J.; Jang, T.; Nam, J.W.; Kim, K.; Kang, K. Identification of bioactive heterocyclic compounds from mulberry and their protective effect against streptozotocin-induced apoptosis in INS-1 cells. *Mol. Med. Rep.*, **2018**, 17(4), 5982-5987.
<http://dx.doi.org/10.3892/mmr.2018.8582> PMID: 29436651
- [30] Lim, S.H.; Yu, J.S.; Lee, H.S.; Choi, C.I.; Kim, K.H. Antidiabetic flavonoids from fruits of *Morus alba* promoting insulin-stimulated glucose uptake via Akt and AMP-activated protein kinase activation in 3T3-L1 adipocytes. *Pharmaceutics*, **2021**, 13(4), 526.
<http://dx.doi.org/10.3390/pharmaceutics13040526> PMID: 33918969
- [31] Ni, Z.; Li, J.; Qian, X.; Yong, Y.; Wu, M.; Wang, Y.; Lv, W.; Zhang, S.; Zhang, Y.; Shao, Y.; Chen, A. *Phellinus igniarius* polysaccharides ameliorate hyperglycemia by modulating the composition of the gut microbiota and their metabolites in diabetic mice. *Molecules*, **2023**, 28(20), 7136.
<http://dx.doi.org/10.3390/molecules28207136> PMID: 37894615
- [32] Liang, D.; Cai, X.; Guan, Q.; Ou, Y.; Zheng, X.; Lin, X. Burden of type 1 and type 2 diabetes and high fasting plasma glucose in Europe, 1990-2019: A comprehensive analysis from the global burden of disease study 2019. *Front. Endocrinol.*, **2023**, 14, 1307432.
<http://dx.doi.org/10.3389/fendo.2023.1307432> PMID: 38152139
- [33] Yu, G.; Fu, X.; Mo, X.; Tan, L.; Yang, S. Multi-target anti-diabetic styrylpyrones from *Phellinus igniarius*: Inhibition of α -glucosidase, protein glycation, and oxidative stress. *Int. J. Biol. Macromol.*, **2024**, 278(Pt 2), 134854.
<http://dx.doi.org/10.1016/j.ijbiomac.2024.134854> PMID: 39168223
- [34] Zheng, M.; Wang, L.; Sun, Y.; Pi, X.; Zhang, W.; Gao, P.; Lu, S.; Liu, W. Hypoglycemic effect of the *Phellinus baumii* extract with α -glucosidase-inhibited activity and its modulation to gut microbiota in diabetic patients. *Biomed. Pharmacother.*, **2023**, 158, 114130.
<http://dx.doi.org/10.1016/j.biopha.2022.114130> PMID: 36577329
- [35] Tang, D.; Liu, L.; Ajiakber, D.; Ye, J.; Xu, J.; Xin, X.; Aisa, H.A. Anti-diabetic effect of *Punica granatum* flower polyphenols extract in type 2 diabetic rats: Activation of Akt/GSK-3 β and inhibition of IRE1 α -XBP1 pathways. *Front. Endocrinol.*, **2018**, 9, 586.
<http://dx.doi.org/10.3389/fendo.2018.00586> PMID: 30374328
- [36] Arun, N.; Singh, D.P. *Punica granatum*: A review on pharmacological and therapeutic properties. *Int. J. Pharm. Sci. Res.*, **2012**, 3(5), 1240-1245.
[http://dx.doi.org/10.13040/IJPSR.0975-8232.3\(5\).1240-45](http://dx.doi.org/10.13040/IJPSR.0975-8232.3(5).1240-45)
- [37] Lee, S.M.; Bae, B.S.; Park, H.W.; Ahn, N.G.; Cho, B.G.; Cho, Y.L.; Kwak, Y.S. Characterization of Korean Red Ginseng (*Panax ginseng* Meyer): History, preparation method, and chemical composition. *J. Ginseng Res.*, **2015**, 39(4), 384-391.
<http://dx.doi.org/10.1016/j.jgr.2015.04.009> PMID: 26869832
- [38] Yang, Z.; Dan Wang; Li, Y.; Zhou, X.; Liu, T.; Shi, C.; Li, R.; Zhang, Y.; Zhang, J.; Yan, J.; Zhu, X.; Li, Y.; Gong, M.; Wang, C.; Yuan, C.; Cui, Y.; Wu, X. Untargeted metabolomics analysis of the anti-diabetic effect of Red ginseng extract in Type 2 diabetes Mellitus rats based on UHPLC-MS/MS. *Biomed. Pharmacother.*, **2022**, 146, 112495.
<http://dx.doi.org/10.1016/j.biopha.2021.112495> PMID: 34891123
- [39] Ji, J.; Yang, X.; Flavel, M.; Shields, Z.P.I.; Kitchen, B. Antioxidant and anti-diabetic functions of a polyphenol-rich sugarcane extract. *J. Am. Coll. Nutr.*, **2019**, 38(8), 670-680.
<http://dx.doi.org/10.1080/07315724.2019.1587323> PMID: 31008696
- [40] Ali, S.E.; Yuan, Q.; Wang, S.; Farag, M.A. More than sweet: A phytochemical and pharmacological review of sugarcane (*Saccharum officinarum* L.). *Food Biosci.*, **2021**, 44, 101431.
<http://dx.doi.org/10.1016/j.fbio.2021.101431>
- [41] Alara, O.R.; Abdurahman, N.H.; Abdul Mudalip, S.K.; Olalere, O.A. Phytochemical and pharmacological properties of *Vernonia amygdalina*: A review. *J. Chem. Eng. Indus. Biotechnol.*, **2017**, 2(1), 80-96.
<http://dx.doi.org/10.15282/jceib.v2i1.3871>
- [42] Ong, K.W.; Hsu, A.; Song, L.; Huang, D.; Tan, B.K.H. Polyphenol-rich *Vernonia amygdalina* shows anti-diabetic effects in streptozotocin-induced diabetic rats. *J. Ethnopharmacol.*, **2011**, 133(2), 598-607.
<http://dx.doi.org/10.1016/j.jep.2010.10.046> PMID: 21035531
- [43] Mohamed, M.A.; Hamed, M.M.; Abdou, A.M.; Ahmed, W.S.; Saad, A.M. Antioxidant and cytotoxic constituents from *Wisteria*

- sinensis*. *Molecules*, **2011**, 16(5), 4020-4030.
<http://dx.doi.org/10.3390/molecules16054020> PMID: 21544041
- [44] Huang, Y.; Zhou, T.; Zhang, Y.; Huang, H.; Ma, Y.; Wu, C.; Wang, Q.; Lin, Q.; Yang, X.; Pang, K. Antidiabetic activity of a flavonoid-rich extract from flowers of *Wisteria sinensis* in type 2 diabetic mice via activation of the IRS-1/PI3K/Akt/GLUT4 pathway. *J. Funct. Foods*, **2021**, 77, 104338.
<http://dx.doi.org/10.1016/j.jff.2020.104338>
- [45] Keskin, S.; Şirin, Y.; Çakır, H.; Keskin, M. Phenolic composition and antioxidant properties of *Wisteria sinensis*. *Int. J. Sci. Technol. Res.*, **2019**, 5(2), 98-103.
<http://dx.doi.org/10.7176/IJSTR/5-2-12>
- [46] Li, G. Q.; Kam, A.; Wong, K. H.; Zhou, X.; Omar, E. A.; Alqahtani, A.; Li, K. M.; Razmovski-Naumovski, V.; Chan, K. Herbal medicines for the management of diabetes. In: *Diabetes. Advances in Experimental Medicine and Biology*; Ahmad, S. I., Ed.; Springer: New York, NY, **2013**; 771, pp. 396-413.
http://dx.doi.org/10.1007/978-1-4614-5441-0_28
- [47] Li, J.; Houseknecht, K.L.; Stenbit, A.E.; Katz, E.B.; Charron, M.J. Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4 knockout mice. *FASEB J.*, **2000**, 14(9), 1117-1125.
<http://dx.doi.org/10.1096/fasebj.14.9.1117> PMID: 10834933
- [48] Vargas, E.; Podder, V.; Carrillo Sepulveda, M.A. Physiology, glucose transporter type 4. In: *StatPearls*; StatPearls Publishing: Treasure Island, FL, **2025**.
- [49] Chen, H.; Xiong, L.; Wang, N.; Liu, X.; Hu, W.; Yang, Z.; Jiang, Y.; Zheng, G.; Ouyang, K.; Wang, W. *Chimonanthus nitens* Oliv. leaf extract exerting anti-hyperglycemic activity by modulating GLUT4 and GLUT1 in the skeletal muscle of a diabetic mouse model. *Food Funct.*, **2018**, 9(9), 4959-4967.
<http://dx.doi.org/10.1039/C8FO00954F> PMID: 30182103
- [50] Zheng, S.; Deng, S.; Huang, Y.; Huang, M.; Zhao, P.; Ma, X.; Wen, Y.; Wang, Q.; Yang, X. Anti-diabetic activity of a polyphenol-rich extract from *Phellinus igniarius* in KK-Ay mice with spontaneous type 2 diabetes mellitus. *Food Funct.*, **2018**, 9(1), 614-623.
<http://dx.doi.org/10.1039/C7FO01460K> PMID: 29271444
- [51] Chukwuma, I.F.; Nworah, F. N.; Apeh, V. O.; Omeje, K. O.; Nweze, E. J.; Asogwa, C. D.; Ezeorba, T. P. C. Phytochemical characterization, functional nutrition, and anti-diabetic potentials of *Leptadenia hastata* (Pers.) Decne leaves: *In silico* and *in vitro* studies. *Bioinform. Biol. Insights*, **2022**, 16, 11779322221115436.
<http://dx.doi.org/10.1177/11779322221115436>
- [52] Ezz, A.M.M.; Zaki, S.; Tabl, G.A. Anti-diabetic effects of pomegranate peel extract and L-carnitine on streptozotocin induced diabetes in rats. *Biomed. Pharmacol. J.*, **2023**, 16(3), 1827-1835.
<http://dx.doi.org/10.13005/bpj/2762>